Intec Pharma ( $NTEC) DD Chain:

Underwritten public offering in February of 16,250,000 shares at $0.40 per share. (with warrants at $0.40)

Closed another offering on May 6 of 16,291,952 shares at a price of $0.30690 per share. (with warrants at $0.245)

NTEC is currently trading below these.

From first quarter financial results (released March 31):

Research expenses: down 76%
Administrative/General expenses: down 23%
Net loss: down 64%
Loss per share: down 75%

Cash on hand: $10.9M (pre May offering number)

(picture from March 5th presentation)

Their baby is the Accordion Pill (which is PROPRIETARY)

This is beneficial for drugs that:
- have a narrow absorption window
- are poorly soluble
- act in the stomach or upper GI tract

Currently applications:
- Parkinson's symptoms treatment
- Pain relief with THC

There is a $200M-$500M market opportunity for their Parkinson's Disease venture.

As for the THC applications, Intec is awaiting receipt of the active ingredients to initiate clinical material production and, "hopefully, advance this program into the clinic LATER THIS YEAR."

Accordion Pill compared to other methods:

Current progress for the Accordion Pill Pipeline

The potential for partnership with Merck in a Phase 3 clinical trial is HUGE

Upcoming (mid-2020, which sounds relatively soon) discussions with Merck for human PK studies.

When $SURF collaborated with Merck...THEIR PRICE TRIPLED

These discussions should be successful, as Intec has TWO members on its board formerly involved with Merck.

Summary:

Lastly, Sabby Management is not involved.

$NTEC has until Wednesday, August 19th to reach a share price of $1

(Missed March 2nd deadline so they get a 180 day extension to have a closing price of $1+ for ten consecutive days)

https://m.marketscreener.com/INTEC-PHARMA-LTD-10621086/news/INTEC-PHARMA-LTD-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-Standard-29165322/